Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below 200 Day Moving Average – Should You Sell?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.21 and traded as low as $0.88. Eagle Pharmaceuticals shares last traded at $0.88, with a volume of 4,000 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Eagle Pharmaceuticals in a research note on Saturday. They set a “hold” rating for the company.

Eagle Pharmaceuticals Price Performance

The firm has a fifty day moving average of $1.09 and a 200 day moving average of $1.21.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. acquired a new stake in Eagle Pharmaceuticals during the third quarter worth about $453,000. Jane Street Group LLC acquired a new position in Eagle Pharmaceuticals in the 3rd quarter valued at about $96,000. DGS Capital Management LLC grew its stake in shares of Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares during the period. Finally, RBF Capital LLC increased its holdings in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares during the last quarter. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.